

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**IN THE APPLICATION OF:** Cherney :  
**SERIAL NO.:** 10/027,644 :  
**FILED:** December 20, 2001:

**CASE NO.:** PH-7269  
**ART UNIT:** 1614  
**EXAMINER:** Unknown

**FOR: CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY**

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b). Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- ( X ) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.
- ( ) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
- ( ) Certification in Accordance with §1.97(e) is set forth below.
- ( ) The fee of **\$240.00** as set forth in §1.17(p) is attached.
- ( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of **\$130.00** as set forth in §1.17(i)(1)

Please charge any deficiency or credit any overpayment to Deposit Account No. 193880. There are no listed references which are not in the English language.

Respectfully submitted,



Mary K. VanAtten  
Attorney for Applicants  
Registration No. 39,408  
Telephone: 302-467-5268

DATE: August 27, 2002  
Bristol-Myers Squibb Company  
P. O. Box 4000  
Princeton, NJ 08543-4000

RECEIVED  
SEP 03 2002  
TECH CENTER 190012900**Certificate of Mailing under 37 CFR 1.8**In the Application of: **Cherney, Robert**CASE NO.: **PH-7269**APPLICATION NO.: **10/027,644**GROUP ART UNIT: **1614**FILED: **DECEMBER 20, 2001**EXAMINER: **UNKNOWN**FOR: **CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY**

I hereby certify that this correspondence, a Supplemental Information Disclosure Statement (with 1449 and references) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Assistant Commissioner for Patents  
Washington, D.C. 20231

on August 27, 2002  
Date

\_\_\_\_\_  
Signature

Denise Bierlein

\_\_\_\_\_  
Type or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.